MassMutual Private Wealth & Trust FSB Sells 7,399 Shares of Johnson & Johnson $JNJ

Key Points

• MassMutual Private Wealth & Trust FSB cut its Johnson & Johnson stake by 4.1% in the third quarter, selling 7,399 shares and retaining 170,950 shares valued at approximately $45.3 million. Institutional investors and hedge funds collectively own 69.55% of J&J.
• Johnson & Johnson reported quarterly EPS of $2.90, exceeding estimates of $2.84, while revenue rose 6.6% year over year to $25.31 billion. The company also pays a quarterly dividend of $1.34, equivalent to a 2.1% annualized yield.
• Analysts maintain a favorable outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $275.87. However, Stelara biosimilar competition remains a key near-term risk, despite growth prospects from oncology and newer immunology products.

MassMutual Private Wealth & Trust FSB lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 170,950 shares of the company's stock after selling 7,399 shares during the period. Johnson & Johnson accounts for about 1.2% of MassMutual Private Wealth & Trust FSB's portfolio, making the stock its 20th largest position. MassMutual Private Wealth & Trust FSB's holdings in Johnson & Johnson were worth $45,257,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Silver Coast Investments LLC grew its holdings in Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV lifted its position in shares of Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management grew its stake in shares of Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after purchasing an additional 39 shares during the last quarter. Denali Advisors LLC grew its stake in shares of Johnson & Johnson by 1.2% during the second quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock valued at $839,000 after purchasing an additional 40 shares during the last quarter. Finally, Beaird Harris Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 1.8% in the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock valued at $501,000 after purchasing an additional 42 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Down 0.0%

Shares of NYSE JNJ opened at $255.94 on Monday. Johnson & Johnson has a fifty-two week low of $182.94 and a fifty-two week high of $281.07. The firm has a market capitalization of $616.79 billion, a P/E ratio of 29.66, a P/E/G ratio of 2.52 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company's 50 day simple moving average is $266.37 and its 200 day simple moving average is $248.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts predict that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is currently 62.11%.

Wall Street Analyst Weigh In

Several research firms have issued reports on JNJ. Morgan Stanley upped their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. The Goldman Sachs Group reissued a "buy" rating and issued a $282.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. Citigroup boosted their target price on Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Guggenheim upped their price target on Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $275.87.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: ICOTYDE delivers durable psoriasis results: New Phase 3 ICONIC-TOTAL data showed sustained skin clearance through two years. At Week 112, 70% of patients achieved clear or almost clear skin, while complete clearance reached 89% for genital psoriasis and 60% for scalp psoriasis, with no new safety concerns reported. The results support ICOTYDE as a potential important first-line systemic treatment and strengthen J&J’s immunology pipeline. J&J ICOTYDE psoriasis data
• Positive Sentiment: Innovative Medicine growth remains a key offset: Analysts expect oncology products and newer launches to drive another quarter of growth, helping counter revenue erosion from Stelara biosimilars. This supports the investment case that J&J can replace lost exclusivity revenue with newer products. Innovative Medicine Q3 growth drivers
• Positive Sentiment: IMAAVY adds pipeline support: New data in generalized myasthenia gravis gives investors additional evidence that J&J’s immunology portfolio could provide future growth beyond current blockbuster medicines. IMAAVY data update
• Neutral Sentiment: J&J continues to receive favorable valuation commentary and analyst support after a strong one-year advance, but its approximately 30-times earnings valuation leaves less room for disappointment.
• Negative Sentiment: Stelara biosimilar pressure remains the central risk: The expected decline in Stelara sales is weighing on near-term growth comparisons and may be contributing to investor caution despite positive pipeline news.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.